Sumitomo Pharma Co., Ltd.
View on Our Report (Response to Gotham City Research LLC’s August 7, 2026 Report)
Publicizing our view on GCR's report. Describes approval review for amsucaplate? and plan for Ph4 trials, and indicates consideration of appropriate legal actions.
Key Figures
- Amshaypry: Approval conditions and Ph4 trial plan (Unknown)
- GCR report date: 2026-08-07, view on financial reporting (Unknown)
- Possibility of legal action (Unknown)
AI要約
Key Points of the News
This release presents Sumitomo Pharma's view on the August 7, 2026 report from Gotham City Research LLC. The report makes claims regarding short positions in the company's stock; the company states it will not accept them. Amshaypry? is a product developed in collaboration with Kyoto University and others, and the reliability of the approval review materials has been confirmed through regulatory review. The company plans to properly conduct Ph4 trials, accumulate evidence of efficacy and safety, and aim for early full approval. We will continue to disclose information in a timely and appropriate manner.
Future Actions & Impact
Indicates the possibility of taking appropriate actions, including legal measures, against the one-sided views in GCR's financial reporting. Will act as necessary to protect shareholders and investors' interests.
Sumitomo Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
